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Background. Naturally occurring Foxp3+regulatory T cells play an important role in the inhibition of an immunological attack
of the fetus. As implantation of the fetus poses an immediate antigenic challenge, the immune system has to prepare itself for
this event prior to implantation. Methodology and Principal Findings. Here, we show using quantitative RT-PCR and flow
cytometry that regulatory T cells accumulate in the uterus not only during pregnancy, but also every time the female becomes
fertile. Their periodic accumulation is accompanied by matching fluctuations in uterine expression of several chemokines,
which have been shown to play a role in the recruitment and retention of regulatory T cells. Conclusions/Significance. The
data lead us to propose that every time a female approaches estrus, regulatory T cells start to accumulate in the uterus in
preparation for a possible implantation event. Once pregnancy is established, those regulatory T cells that have seen
alloantigen need to be retained at their site of action. Whilst several chemokines appear to be involved in the recruitment and/
or retention of regulatory T cells during estrus, in pregnancy this role appears to be taken over by CCL4.
Citation: Kallikourdis M, Betz AG (2007) Periodic Accumulation of Regulatory T Cells in the Uterus: Preparation for the Implantation of
a Semi-Allogeneic Fetus?. PLoS ONE 2(4): e382. doi:10.1371/journal.pone.0000382
INTRODUCTION
Naturally occurring Foxp3+regulatory T cells play an important
role in the prevention of legitimate immune responses that would
have deleterious effects on the organism if left unchecked. They
prevent autoimmunity [1] as well as an overreaction to commensal
bacteria [2] and chronic infection [3]. More recently we have
demonstrated that they also mediate maternal tolerance to the
fetus. In the absence of regulatory T cells the maternal immune
system recognises the semi-allogeneic fetus as foreign and attacks it
[4]. Pregnancy itself induces a systemic expansion of the pool of
regulatory T cells that starts already prior to implantation and is
independent of exposure to alloantigen [4]. Those regulatory T
cells that have experienced antigen turn into CCR5+effector
regulatory T cells, which preferentially accumulate in the gravid
uterus [5]. Whether the exposure to fetal antigen occurs in the
uterus itself or in a draining secondary lymph organ is unclear.
However, interference with the accumulation of effector regula-
tory T cells at their site of action severely impedes their function
[5–7]. A hint that the accumulation of regulatory T cells in the
gravid uterus is of equal importance in human pregnancies comes
from the finding that the number of decidual regulatory T cells in
spontaneous abortions is dramatically decreased [8].
The implantation of the fetus expressing paternal transplanta-
tion antigens represents a strong antigenic insult, which should
lead to an immediate immunological response. The most effective
way for the immune system to deal with this problem is to stop
such an anti-fetal response at its initiation. Thus one might expect
that mechanisms have evolved that prepare the uterus for a possible
implantation event. One way to achieve this would be by increasing
the likelihood of regulatory T cells encountering paternal alloanti-
gen, by systemic expansion of their number towards estrus [9] and by
increasing their presence in the uterus in preparation for
implantation. As the paternal alloantigen cannot be known to the
immune system prior to implantation both are likely to be antigen
independent events. Following implantation one might expect those
regulatory T cells that recognize paternal alloantigen to be
preferentially retained. Indeed, antigen-experienced CCR5+effector
regulatory T cells accumulate in the uterus during pregnancy [5].
Here we demonstrate that the number of regulatory T cells
present in the uterus is subject to periodic fluctuations. Every time
the female approaches estrus regulatory T cells accumulate in the
uterine tissue. This fluctuation goes hand in hand with a similar
rise and fall in the expression levels of several chemokines that
have been shown to be involved in the recruitment and/or
retention of regulatory T cells. However, only one of these
chemokines, CCL4, remains highly elevated during pregnancy.
This concurs with a switch from the accumulation of all regulatory
T cells to preferential accumulation of antigen experienced
CCR5+effector regulatory T cells [5]. Thus we suggest that every
time a female becomes fertile the uterus prepares itself by
recruiting regulatory T cells even prior to an implantation event.
RESULTS
Periodic accumulation of regulatory T cells in the
uterus
Regulatory T cells accumulate in the gravid uterus [4]. This can
be measured as an increase in the level of Foxp3 mRNA in the
uteri from pregnant mice over that of non-pregnant mice. Whilst
Foxp3 levels in the uteri of non-pregnant mice are consistently
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lower, we observed substantial mouse-to-mouse variation. This led
us to examine whether the number of regulatory T cells in the
uterus fluctuates with the estrus cycle. We could distinguish the
four phases of estrus by the variations in the abundance of the cell
types present in vaginal lavages. Di-estrus is characterized by the
presence of leukocytes and epithelial cells. This is followed by pro-
estrus, which can be identified based on the presence of epithelial
cells that are close to cornification but still have visible nuclei and
cornified epithelial cells. Lavages taken during estrus contain
exclusively cornified epithelial cells. The return of leukocytes
amongst the cornified cells is characteristic of met-estrus [10].
In order to obtain an approximation of the number of
regulatory T cells in the uterus at the various phases of the estrus
cycle, we measured the level of Foxp3 mRNA in whole uterine
tissue by quantitative RT-PCR (Fig. 1). We found that the uterine
Foxp3 levels were lowest in di-estrus. There was a statistically
significant increasing trend (p = 0.0005, post test for linear trend)
in Foxp3 levels from di-estrus to estrus. The uterine Foxp3 levels at
estrus and in pregnant mice were significantly elevated compared
to the levels observed at di-estrus (p = 0.0073 and p= 0.0065
respectively; t test). These results show that regulatory T cells
periodically accumulate in the uterus, peaking during the estrus
and then declining until the next approach of estrus. If, however,
the mouse becomes pregnant, the level of Foxp3 remains high,
reflecting a more long-term accumulation of these cells in the
uterus. As we did not correct for variations in uterine size, the
levels of Foxp3 might be an underestimate of regulatory T cell
numbers during estrus as uteri approaching this phase are
substantially enlarged. The same applies in the case of pregnancy.
Thus the periodic accumulation of regulatory T cells might be
even more pronounced than our data suggest.
Chemokine expression in the uterus
Several chemokines have been reported to be expressed in the
uterus at the various stages of the estrus cycle and during
pregnancy. As we are mainly interested in the recruitment and
retention of regulatory T cells to the uterus we restricted our
analysis to CCL3, CCL4, CCL5, CCL22 and CX3CL1, all of
which have been implicated in the regulation of T cell trafficking.
CX3CL1 has been shown to be expressed in glandular epithelial
cells [11] and decidual stroma [12]. It is thought to be involved in
the adhesion of T cells to endothelial cells [13] and its receptor,
CX3CR1 can be detected on regulatory T cells [14]. CCL22 is the
ligand for CCR4 [15] and has been shown to recruit both
activated T cells [16] and regulatory T cells [17,18]. It is expressed
by the uterine epithelium and decidualized stroma [19]. CCL3,
CCL4, CCL5 are all ligands of CCR5, which is expressed on both
pro-inflammatory effector T cells [5,20] and effector regulatory T
cells [5]. These chemokines are expressed by glandular epithelium,
endothelium and stromal cells [12,19,21–23].
To examine variations in the uterine expression of these chemo-
kines during the estrus cycle and pregnancy, we measured the
mRNA levels of the same set of uteri used for the Foxp3 analysis.
In about half of the samples the mRNA levels for CCL5 was below
the limit of detection (data not shown) hindering a detailed
statistical analysis. All the other chemokines exhibited a statistically
significant rising trend from di-estrus to estrus (CCL3: p = 0.01,
CCL4: p= 0.019, CCL22: p = 0.017 and CX3CL1: p= 0.004;
post test for linear trend).
Whilst the expression of all these chemokines was elevated during
estrus compared to di-estrus (Fig. 2a–d), with similar linear trends
(Fig. 3a), only CCL4 retained a statistically significantly elevated
expression (p,0.0001; t-test) during pregnancy (Fig. 2b). This is
reflected in the steep slope of the linear trend from di-estrus to
pregnancy (Fig. 3b), which is highly significant for CCL4
(p,0.0001, post test for linear trend).
Accumulation of effector regulatory T cells in the
gravid uterus
There is a direct correlation between the level of uterine CCL4
expression and the presence of regulatory T cells as reflected by
the Foxp3 level. This is highlighted by the almost identical rising
trends from di-estrus to pregnancy (Fig. 3c and d), which in both
cases are highly significant (p,0.0001, post test for linear trend).
The shift from the elevated expression of multiple chemokines
during estrus to the elevated expression of only CCL4 during
pregnancy (Fig. 2) might cause a change in the type of cell
recruited and/or retained. Indeed, we found that during estrus
only half of the regulatory T cells in the uterus were
CCR5+(Fig. 3e) whereas we regularly found more than 70% of
regulatory T cells in the gravid uterus expressing CCR5+(Fig. 3f).
Furthermore, the total number of CCR5+regulatory T cells in the
uterus as a proportion of all uterine cells increases significantly
(Fig. 3i) (p = 0.036; non parametric test). Both, at estrus and
E10.5 of pregnancy, over 90% of CD4+CD25+cells are
Foxp3+(Fig. 3g and h), confirming that the vast majority of
the cells are indeed regulatory T cells rather than freshly induced
proinflammatory effector T cells. Considering that the uterus also
increases substantially in size during pregnancy, the increase in
CCR5+regulatory T cells is even more marked.
When plotted in temporal sequence, the fluctuations in Foxp3,
CCL3, CCL4 fit a sinusoidal curve peaking at estrus and with
a minimum at di-estrus (Fig. 4a–c). It is noteworthy that this is
not the case for the other three chemokines examined (Fig. 4d–f).
This excludes that the fluctuations observed are a simple reflection
Figure 1. Variation of Foxp3 expression in the uterus during the
mouse estrus cycle and pregnancy. Relative levels of Foxp3 were
determined by quantitative RT-PCR performed on total uterine mRNA.
Uteri were isolated from non-pregnant or pregnant mice at E10.5 (mid-
gestation). The estrus cycle phase of non-pregnant mice was de-
termined by vaginal smear and mice were categorised into 4 groups,
according to their estrus cycle phase. Foxp3 levels for the 4 phases are
shown in chronological order and compared to the levels in pregnant
mice. Each point corresponds to one animal. Horizontal bars represent
the mean of each data set. Dotted lines indicate the maximal and
minimal values detected for pregnant mice. The red line indicates the
linear trend (linear regression, displayed on logarithmic scale) for the
phases approaching estrus. The experiment was performed on 37 non-
pregnant and 10 pregnant mice. HPRT mRNA expression levels were
used for normalisation. PCR assays were performed in triplicate.
doi:10.1371/journal.pone.0000382.g001
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of fluctuations in HPRT levels, which were used for normalisation
of the samples.
DISCUSSION
The fetus represents a semi-allograft and thus a strong antigenic
insult. Given the importance of placental implantation for
mammalian propagation this is far from an ideal scenario from
an immunological perspective. Indeed, it might be the reason why
regulatory T cells have evolved in the first place [24]. The
expansion of the regulatory T cell pool during pregnancy starts
before implantation [4]. This might be the way by which the
immune system attempts to enhance the likelihood that a particular
set of paternal alloantigens can be detected by regulatory T cells.
According to this hypothesis, regulatory T cells first expand in
number so as to increase the chance that paternally-derived
alloantigens will be recognized. Once this has occurred, the
emphasis switches to the retention of those regulatory T cells that
have been activated by the alloantigen, at their site of action [6,7].
In the case of pregnancy this is most likely the uterus [5].
Our data shows that the uterine expression of all chemokines
analyzed displays periodic variation peaking around estrus
(Fig. 4). This is in agreement with the notion that chemokines
are involved in the remodelling of the uterine architecture and cell
composition during the estrus cycle [19,25]. All these chemokines
are also involved in T cell recruitment and retention [15].
Interestingly, all three ligands (CCL3, CCL4, CCL5) for CCR5
are expressed at an elevated level during estrus. CCR5 is expressed
by the effector arm of both pro-inflammatory and regulatory T
cells [5,20]. It is tempting to speculate that this can lead to an
accumulation of both cell types during estrus. Under favourable
health conditions the balance between regulatory T cells to pro-
inflammatory T cells would be in favour of the regulatory cells
(Fig. 3 g and h) [4,8] and indeed we can measure this in the form
of a significant increase in Foxp3 mRNA in the uterus (Fig. 1).
In contrast, during an infection pregnancy might become an
undesirable high-risk event. This is particularly the case when the
urogenital tract is affected [26]. In this scenario the prevention of
an implantation of the fetus might be of advantage for the mother
[27]. The recruitment of abundant pro-inflammatory CCR5+ef-
fector T cells to the uterus would be likely to lead to a loss of
tolerance. Indeed, an experimentally induced increase in pro-
inflammatory CCR5+effector T cells has been demonstrated to
cause an increase in abortions [20].
All the chemokines analyzed have the potential to influence the
accumulation of regulatory T cells in the uterus during estrus, as
their corresponding receptors are expressed on regulatory T cells
[5–7,14,17–18]. However, CCL4 is the only chemokine with
elevated expression during pregnancy. Given the fact that
Figure 2. Variation of chemokine expression in the uterus during the mouse estrus cycle and pregnancy. Relative levels of (a) CCL3, (b) CCL4, (c)
CCL22 and (d) CX3CL1 were determined by quantitative RT-PCR performed on total uterine mRNA, normalised to HPRT on the same sample set used
in Fig. 1. Levels for the 4 estrus cycle phases are shown in chronological order and compared to the levels in pregnant mice. Each point corresponds
to one animal. Horizontal bars represent the mean of each data set. Dotted lines indicate the maximal and minimal values detected for pregnant
mice.
doi:10.1371/journal.pone.0000382.g002
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Figure 3. Chemokine fluctuation approaching estrus and pregnancy. Linear trends for the fluctuation of chemokine expression levels (same sample
set used in Figs. 1 and 2) during (a) the phases approaching estrus (diestrus.pro-estrus.estrus) and (b) the phases approaching estrus and
pregnancy. (c,d): Linear trends for the fluctuation of (c) Foxp3 and (d) CCL4 expression levels during the phases approaching estrus and pregnancy.
Dots represent the mean of each data set. Dotted curves represent the 95% confidence interval of the trend line. (e–i) CCR5+regulatory T cells in the
uterus of mice at estrus or at mid-gestation. n = 3 for estrus, each sample pooled from 3 mice; n = 5 for pregnant, one mouse per sample. Uterine cells
were isolated from C57BL/6 mice (e,g) at estrus or (f,h) at E10.5 (mid-gestation) after allogeneic mating and analyzed by FACS for the expression of
(e,f) CD4, CD25 and CCR5 or (g,h) CD4, CD25 and Foxp3. (e,f) Plots show CD25 and CCR5 surface expression for all CD4+gated cells. Number in top
right corner denotes the percentage of CCR5+cells amongst CD4+CD25+cells. 16106 ‘total’ uterine cells collected; all CD4+cells shown. (g,h)
Histograms show intracellular Foxp3 stain in (red) CD4+CD25+or (blue) CD4+CD252 cells. Representative samples are shown. (i) Uterine cells from
C57BL/6 mice at estrus or at E10.5 of allogeneic pregnancy were analyzed by FACS. The percentage of CD4+CD25+CCR5+cells amongst all uterine cells
is shown.
doi:10.1371/journal.pone.0000382.g003
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alloantigen-experienced effector regulatory T cells express CCR5
[5–6], it is likely that CCL4 is responsible for the retention of these
cells in the gravid uterus [5].
Our data show that every time a female becomes fertile
regulatory T cells start to accumulate in the uterus. Regulatory T
cells may be actively recruited to the uterus in order to be exposed
to paternal alloantigen upon implantation. Those regulatory T
cells that recognize paternal alloantigen become activated, up-
regulate CCR5 and thus are retained in the uterus. Alternatively
the expression of these chemokines might be in preparation for the
passive accumulation by preferential recruitment and/or retention
of those regulatory T cells that encounter paternal alloantigen in
the draining lymph nodes, become activated and up-regulate
CCR5. In this scenario the accumulation of regulatory T cells
during estrus might simply be a side effect of the uterus getting
ready to retain those regulatory T cells that will become activated
by alloantigen. Whether the cells see alloantigen in the uterus itself
or get activated in the secondary lymphoid organs will be subject
of future investigation.
MATERIALS AND METHODS
Experimental animals
Mice were kept in specific pathogen-free conditions. All mice used
in the quantitative PCR studies were of BALB/c6C57BL/6 F1
background. Mice were identified as being in di-estrus, pro-estrus,
Figure 4. Foxp3 and chemokine expression level fluctuations during the estrus cycle and pregnancy. Plots of the variation of the mean relative
expression of Foxp3, CCL3, CCL4, CCL5, CCL22 and CX3CL1 during the estrus cycle phases and pregnancy (same sample set used in Figs. 1 and 2).
Estrus cycle phases are arranged in chronological order: (d) diestrus.(p) pro-estrus.(e) estrus.(m) met-estrus.(d) diestrus etc. After 2 full cycles,
a cycle were estrus is followed by (P) pregnancy is shown. Dots represent the mean of each data set. Sinusoidal functions (black lines) were fitted to
the estrus cycle data (see methods). In the cases where the sinusoidal function did not fit the data, a line connecting the means is shown (red line).
Dotted lines join the mean of the estrus phase of the last cycle with the mean of the levels detected during pregnancy.
doi:10.1371/journal.pone.0000382.g004
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estrus or met-estrus by Giemsa (Sigma-Aldrich, UK) staining of
smears of vaginal lavages, as per manufacturer’s instructions [10].
C57BL/6 females were used for the ‘estrus versus pregnant’
comparison in which the pregnant mice were allogeneically mated
by BALB/c males.
Preparation of uterine tissue
Whole uteri were separated from surrounding tissue (including
fetuses/placenta in the case of the pregnant mice). For flow
cytometric analysis the uteri were digested in collagenase A (Roche
Diagnostics, UK) for 15min according to manufacturer’s instruc-
tions, washed in PBS and then gently pushed through a (60mm
diameter pore size) cell strainer (BD, UK) before being
resuspended in PBS/2%FCS for counting and staining. For
RNA purification, the tissue was immersed in liquid nitrogen,
pulverized and re-suspended in RNA lysis buffer. Total RNA was
prepared using RNeasy kit (Qiagen, UK) incl. on-column DNase
digestion, according to manufacturer’s instructions.
Quantitative real-time RT-PCR
cDNA was synthesized using SuperscriptII RT (Invitrogen, UK),
with random hexamer primers, as per manufacturer’s instructions.
Real time PCR was performed using Taqman universal PCR
master mix (Applied Biosystems, UK) and primers and a fluores-
cent TaqMan probe specific for each gene analyzed or HPRT
(used for normalization). An ABI prism 7700 sequence detection
system was used for 45 cycles of PCR. PCRs were set up at least in
triplicate. The sequences were: Foxp3 primers as in [28], CCL3-
primers: 59-CCA AGT CTT CTC AGC GCC ATA-39 and
59-GAT GAA TTG GCG TGG AAT CTT C-39; CCL3-probe:
59-FAM-AGC TGA CAC CCC GAC TGC CTG C-TAMRA-39;
CCL4-primers: 59-TGC TCG TGG CTG CCT TCT-39 and
59-CTG CCG GGA GGT GTA AGA GA-39; CCL4-probe:
59-FAM-TGC TCC AGG GTT CTC AGC ACC AAT G-
TAMRA-39; CCL5-primers: 59-CTG TCA TCG CTT GCT
CTA GTC CTA-39 and 59-CGG ATG GAG ATG CCG ATT T-
39; CCL5-probe: 59-FAM-ATC CCC TAC TCC CAC TCC
GGT CCT G-TAMRA-39, CCL22-primers 59-CAG GTC CCT
ATG GTG CCA AT-39 and 59-AAC GTG ATG GCA GAG
GGT G-3; CCL22-probe: 59-FAM-AAG ACA GTA TCT GCT
GCC AGG ACT ACA TCC G-TAMRA-39 HPRT-primers: 59-
TTA AGC AGT ACA GCC CCA AAA TG-39 and 59-CAA ACT
TGT CTG GAA TTT CAA ATC C-39 and HPRT probe: 59-
VIC-CCT TTT CAC CAG CAA GCT TGC AAC CTT A-
TAMRA-39. CX3CL1 mRNA quantitation was performed using
a CX3CL1 TaqMan Gene Expression Assay (Mm00436454)
(Applied Biosystems, UK).
Flow cytometric analysis
Cells were labelled with fluorescein isothiocyanate (FITC)-anti-
CD25 (7D4), phycoerythrin (PE)-anti-CCR5 (C34-3448), (Cy)-
anti-CD4 (L3T4)(H129.19) and analyzed on a FACScan. Phyco-
erythrin (PE)-Rat IgG2c was used as isotype control for the CCR5
stain (all antibodies were purchased from BD, UK). Foxp3 intra-
cellular staining was performed using (PE)-anti-Foxp3 kit (eBios-
ciences, US) after permeabilisation of the surface stained cells
according to manufacturer’s instructions.
Statistical analysis
All statistical analysis was performed using the Prism package
(Graphpad, US). Trendlines were fitted by linear regression.
Sinusoidal functions of the fluctuations during the estrus cycle
were constrained by assuming the period to be equal to 1 full
estrus cycle, the amplitude to be equal to half the maximal
variation of the mean value during one full cycle, and the baseline
to be equal to the lowest value of the mean during one full cycle
plus one amplitude
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